Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study
- Registration Number
- NCT06006611
- Lead Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Brief Summary
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
- Detailed Description
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 4201
The COVID-19 positive patients
- patients treated with both azvudine and monotamivir;
- patients receiving other antiviral drugs such as nematavir/ritonavir;
- age < 18 years old
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Azvudine group Azvudine Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;
- Primary Outcome Measures
Name Time Method All-cause mortality of COVID-19 patients Time from onset to death All-cause mortality of COVID-19 patients
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Fifth Affiliated Hospital of Sun Yat-sen University
🇨🇳Zhuhai, Guangdong, China